We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$8.02B
AUM Growth
+$201M
(+2.6%)
Cap. Flow
-$89M
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
19.81%
Holding
867
New
76
Increased
308
Reduced
302
Closed
63
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$48.8M |
| 2 |
Procter & Gamble
PG
|
+$24.6M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$23.6M |
| 4 |
Keysight
KEYS
|
+$23.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$21.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$46.5M |
| 2 |
ExxonMobil
XOM
|
+$36.6M |
| 3 |
GG
Goldcorp Inc
GG
|
+$24.9M |
| 4 |
Walt Disney
DIS
|
+$23.8M |
| 5 |
NAVG
Navigators Group Inc
NAVG
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.16% |
| 2 | Technology | 16.87% |
| 3 | Financials | 10.38% |
| 4 | Consumer Discretionary | 9.09% |
| 5 | Communication Services | 7.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Roper Technologies
ROP
$36.3B
| $5.49M | 0.07% |
15,045
-2,536
| -14% | -$900K |
|
302
Guardant Health
GH
$19.5B
| $5.49M | 0.07% |
14,790
+8,590
| +139% | +$656K |
|
303
Norfolk Southern
NSC
$78.8B
| $5.47M | 0.07% |
22,524
-4,277
| -16% | -$848K |
|
304
Enanta Pharmaceuticals
ENTA
$372M
| $5.46M | 0.07% |
65,000
| – | – |
|
305
PNC Financial Services
PNC
$100B
| $5.45M | 0.07% |
39,899
-81
| -0.2% | -$10.7K |
|
306
Bread Financial
BFH
$4.21B
| $5.36M | 0.07% |
48,104
+12,038
| +33% | +$1.46M |
|
307
Fidelity National Information Services
FIS
$21.5B
| $5.35M | 0.07% |
43,794
+18,958
| +76% | +$2.23M |
|
|
MRSH
308
Marsh
MRSH
$86.3B
| $5.33M | 0.07% |
53,670
-5,250
| -9% | -$502K |
|
309
MGM Resorts International
MGM
$11.7B
| $5.29M | 0.07% |
185,859
+121,334
| +188% | +$3.24M |
|
310
Marriott International
MAR
$98.7B
| $5.26M | 0.07% |
29,605
-10,078
| -25% | -$1.34M |
|
|
PTLA
311
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $5.25M | 0.07% |
194,300
| – | – |
|
312
CF Industries
CF
$19.2B
| $5.22M | 0.07% |
112,226
-32,463
| -22% | -$1.41M |
|
313
Aramark
ARMK
$15B
| $5.21M | 0.07% |
201,128
+61,304
| +44% | +$1.43M |
|
314
Ross Stores
ROST
$76.6B
| $5.19M | 0.06% |
52,552
-17,392
| -25% | -$1.7M |
|
315
Dow Inc
DOW
$21.6B
| $5.16M | 0.06% |
+105,114
| New | +$5.55M |
|
316
Corning
GLW
$126B
| $5.15M | 0.06% |
155,565
-20,818
| -12% | -$668K |
|
317
Walmart Inc
WMT
$871B
| $5.09M | 0.06% |
138,822
+53,127
| +62% | +$1.83M |
|
318
Fortinet
FTNT
$112B
| $5.09M | 0.06% |
332,530
+46,830
| +16% | +$771K |
|
319
Target
TGT
$62.1B
| $5.03M | 0.06% |
47,300
-17,753
| -27% | -$1.43M |
|
320
FedEx
FDX
$74.5B
| $4.99M | 0.06% |
30,508
-18,663
| -38% | -$3.27M |
|
321
Baker Hughes
BKR
$56.8B
| $4.94M | 0.06% |
201,612
+44,476
| +28% | +$1.07M |
|
322
Republic Services
RSG
$66.7B
| $4.94M | 0.06% |
25,214
-13,459
| -35% | -$1.12M |
|
323
Illinois Tool Works
ITW
$81.4B
| $4.94M | 0.06% |
32,923
-2,722
| -8% | -$411K |
|
324
EOG Resources
EOG
$78B
| $4.91M | 0.06% |
52,977
-120,472
| -69% | -$11.2M |
|
325
Pembina Pipeline
PBA
$29.9B
| $4.86M | 0.06% |
130,873
+90,962
| +228% | +$3.31M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2019 Portfolio in Review
As of Q2 2019, Candriam SCA held 867 positions worth $8.02B, up 2.6% from $7.82B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Candriam SCA's Q2 2019 filing shows 76 new, 308 increased, 302 reduced and 63 closed positions. Its largest new stake was Total System Services, Inc.: 112,342 shares worth $14.3M. The largest sale was Celgene Corp, an estimated $46.5M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q2 2019 buy was Total System Services, Inc.: 112,342 shares worth $14.3M.
- Candriam SCA added most to Vertex Pharmaceuticals in Q2 2019, an estimated $48.8M increase.
- Candriam SCA's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $46.5M.
- Candriam SCA fully exited Goldcorp Inc in Q2 2019, selling an estimated $24.9M.
- Candriam SCA's ten largest holdings make up 20% of its $8.02B portfolio in Q2 2019.
- Candriam SCA opened 76 new positions and closed 63 in Q2 2019.
- Candriam SCA's portfolio value rose 2.6% quarter-over-quarter to $8.02B.
Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.